Golden
Sorrento Therapeutics

Sorrento Therapeutics

A pharmaceutical company developing treatments for cancer and chronic diseases

Sorrento Therapeutics is a publicly owned, anti-body centric, clinical stage biopharmaceutical company based in San Diego, California. It develops new treatments for cancer, inflammation, and autoimmune disease. The company aims to turn malignant cancers into manageable and possibly curable disease.

Sorrento's immuno-oncology (I-O) portfolio comprises of a wide array of assets, including a broad fully human antibody library (G-MAB), clinical stage chimeric antigen receptor-T cells (CAR-T), intracellular targeting antibodies (iTAbs), antibody drug conjugates (ADC), and an oncolytic virus (Seprehvir).

Under the I-O category, the company's cross-portfolio asset combination therapies include:

  • CD38 CAR-T -- IND enabling for multiple myeloma
  • CEA CAR-T -- Phase 1 clinical trials for metastatic liver tumors
  • CD38 ADC -- IND enabling

Seprehvir is also under the I-O program and is in the Phase 1 of clinical trials for solid tumors, including glioblastoma, mesothelioma, melanoma, head and neck cancer, pediatric sarcomas, and pediatric neuroblastomas.

Within the pain management category, Sorrento's ZTlido is a lidocaine topical system which is available in the market as of October 2018. They are also developing RTX (resiniferatoxin), a first-class (TRPV1 agonist) non-opioid pain management molecule. As of December 2018, several administration routs are in various stages of Phase 1 trials for terminal cancer pain as well as moderate to severe osteoarthritis pain.

Timeline

Funding rounds

Funding round
Description
Funding round amount (USD)
Funding type
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Alexis Nahama

VP of Corporate Development & President Ark Animal Health

Bill Farley

VP of Sales and Business Development

Deborah H. Telman

Senior VP & General Counsel

Dr. Gunnar F. Kaufmann

Senior VP of Immunotherapy & Head of Research and Global Partnerships

Dr. Henry Ji

Chairman, President, & CEO

Dr. Hui Li

VP of Business Development and GM of China Operations

Jerome B. Zeldis

Chief Medical Officer & President of Clinical Research, Medical Affairs and Regulatory

Jiong Shao

Executive VP & CFO

Mark R. Brunswick

VP of Regulatory Affairs and Quality

Richard B. Alman

Investor

Robert Knight

VP of Clinical Research

Shay Tabani

Employee

Stephen L. Klincewicz

VP of Parmacovigilance and Clinical Operations

William Lees

Employee

Further reading

Title
Author
Link
Type
Date
+ Add new row

Documentaries, videos and podcasts

Title
Date
Link
+ Add new row

Companies

Company
CEO
Location
Products/Services
+ Add new row

News

Title
Author
Date
Publisher
Description
Research and Markets
Invalid Date
www.prnewswire.com:443
DUBLIN, Feb. 14, 2019 /PRNewswire/ -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to...

References